Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: the CENTERA Study

•From baseline to week 76, 65.6% of patients gained ≥15 letters.•In the treat-and-extend phase, 45.0% of patients achieved a mean treatment interval of ≥8 weeks.•A last actual treatment interval of ≥8 weeks was achieved by 63.1% of patients.•Mean BCVA was 51.9 letters at baseline and 72.3 letters at week 76 (+20.3 letters).•Mean central retinal thickness decreased from 759.9 µm at baseline to 265.4 µm at week 76 (−496.1 µm). PurposeTo evaluate...